• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Current Understanding of Post-COVID Pulmonary Fibrosis: Where Are We?

作者信息

Bridi Guilherme das Posses, Tanni Suzana Erico, Baldi Bruno Guedes

机构信息

Divisão de Pneumologia, Instituto do Coração (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de São Paulo, São Paulo, Brazil.

Pulmonology Division of Internal Medicine of Botucatu Medical School, São Paulo State University, Botucatu, Brazil.

出版信息

Arch Bronconeumol. 2023 Feb;59(2):69-70. doi: 10.1016/j.arbres.2022.07.014. Epub 2022 Aug 13.

DOI:10.1016/j.arbres.2022.07.014
PMID:36041958
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9395235/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848d/9395235/b27e339bf86f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848d/9395235/b27e339bf86f/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/848d/9395235/b27e339bf86f/gr1_lrg.jpg

相似文献

1
Current Understanding of Post-COVID Pulmonary Fibrosis: Where Are We?对新冠后肺纤维化的当前认识：我们处于什么阶段？
Arch Bronconeumol. 2023 Feb;59(2):69-70. doi: 10.1016/j.arbres.2022.07.014. Epub 2022 Aug 13.
2
Post covid 19 pulmonary fibrosis. Is it real threat?新冠后肺纤维化。这是真实存在的威胁吗？
Indian J Tuberc. 2021 Jul;68(3):330-333. doi: 10.1016/j.ijtb.2020.11.003. Epub 2020 Nov 10.
3
Pulmonary fibrosis secondary to COVID-19: a narrative review.COVID-19 相关性肺纤维化：一篇叙述性综述。
Expert Rev Respir Med. 2021 Jun;15(6):791-803. doi: 10.1080/17476348.2021.1916472. Epub 2021 Apr 27.
4
Exercise-based pulmonary rehabilitation for a post-COVID-19 pulmonary fibrosis patient: A case report.基于运动的肺康复治疗 COVID-19 后肺纤维化患者：1 例报告。
Medicine (Baltimore). 2021 Nov 24;100(47):e27980. doi: 10.1097/MD.0000000000027980.
5
Discharge may not be the end of treatment: Pay attention to pulmonary fibrosis caused by severe COVID-19.出院并不意味着治疗结束：注意重型 COVID-19 引发的肺纤维化。
J Med Virol. 2021 Mar;93(3):1378-1386. doi: 10.1002/jmv.26634. Epub 2020 Nov 1.
6
COVID-related fibrosis: insights into potential drug targets.COVID 相关纤维化：潜在药物靶点的新见解。
Expert Opin Investig Drugs. 2021 Dec;30(12):1183-1195. doi: 10.1080/13543784.2021.2010188. Epub 2021 Dec 1.
7
Pulmonary Fibrosis in the Time of COVID-19.新冠疫情时期的肺纤维化
Arch Bronconeumol. 2022 Apr;58 Suppl 1:6-7. doi: 10.1016/j.arbres.2022.03.007. Epub 2022 Apr 15.
8
Clinical characteristics and outcomes of post-COVID-19 pulmonary fibrosis: A case-control study.COVID-19 后肺纤维化的临床特征和结局：一项病例对照研究。
Medicine (Baltimore). 2022 Jan 21;101(3):e28639. doi: 10.1097/MD.0000000000028639.
9
Efficacy of the combination of modern medicine and traditional Chinese medicine in pulmonary fibrosis arising as a sequelae in convalescent COVID-19 patients: a randomized multicenter trial.新冠肺炎恢复期继发肺纤维化患者采用中西医结合治疗的疗效：一项随机多中心试验。
Infect Dis Poverty. 2021 Mar 18;10(1):31. doi: 10.1186/s40249-021-00813-8.
10
Phase 1 trial for treatment of COVID-19 patients with pulmonary fibrosis using hESC-IMRCs.使用人胚胎干细胞诱导的间充质干细胞治疗新冠肺炎合并肺纤维化患者的1期试验。
Cell Prolif. 2020 Dec;53(12):e12944. doi: 10.1111/cpr.12944. Epub 2020 Oct 26.

引用本文的文献

1
Equivocating and Deliberating on the Probability of COVID-19 Infection Serving as a Risk Factor for Lung Cancer and Common Molecular Pathways Serving as a Link.关于新冠病毒感染作为肺癌危险因素的可能性及作为联系的常见分子途径的模棱两可与深思熟虑
Pathogens. 2024 Dec 6;13(12):1070. doi: 10.3390/pathogens13121070.
2
The Role of Cytokines and Molecular Pathways in Lung Fibrosis Following SARS-CoV-2 Infection: A Physiopathologic (Re)view.细胞因子和分子通路在SARS-CoV-2感染后肺纤维化中的作用：生理病理学（再）综述
Biomedicines. 2024 Mar 13;12(3):639. doi: 10.3390/biomedicines12030639.
3
Beyond the Acute Phase: Long-Term Impact of COVID-19 on Functional Capacity and Prothrombotic Risk-A Pilot Study.
超越急性期：COVID-19 对功能能力和血栓前风险的长期影响——一项初步研究。
Medicina (Kaunas). 2023 Dec 27;60(1):51. doi: 10.3390/medicina60010051.
4
Risk factors for the development of interstitial lung disease following severe COVID-19 pneumonia and outcomes of systemic corticosteroid therapy: 3-month follow-up.重症新型冠状病毒肺炎后间质性肺疾病发生的危险因素及全身糖皮质激素治疗的结局：3个月随访
Sarcoidosis Vasc Diffuse Lung Dis. 2023 Sep 13;40(3):e2023029. doi: 10.36141/svdld.v40i3.14418.
5
Oxidative Biomarkers Associated with the Pulmonary Manifestation of Post-COVID-19 Complications.与新冠后并发症肺部表现相关的氧化生物标志物
J Clin Med. 2023 Jun 25;12(13):4253. doi: 10.3390/jcm12134253.